MCID: PTT006
MIFTS: 55

Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 12 58 29 54 15 71
Pituitary Neoplasms 43 71
Pituitary Adenomas 36 15
Adenoma of the Pituitary Gland 12
Pituitary Gland Adenoma 17
Adenoma, Pituitary 39

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:3829
KEGG 36 H01102
MeSH 43 D010911
NCIt 49 C3329
SNOMED-CT 67 128664001 254956000
ICD10 via Orphanet 33 D35.2
UMLS via Orphanet 72 C0032000
Orphanet 58 ORPHA99408
UMLS 71 C0032000 C0032019

Summaries for Pituitary Adenoma

KEGG : 36 Pituitary adenomas are an important and frequently occurring form of intracranial tumor. They are usually benign but can give rise to severe clinical syndromes due to hormonal excess, or to visual/cranial disturbances due to mass effect. The tumor can be clinically nonfunctioning or hormone secreting. Among the latter, prolactin (PRL) and growth hormone (GH)-secreting adenomas are the most common. The majority of pituitary adenomas arise sporadically, although a subset occurs as component tumors of well-characterized familial cancer syndromes, such as multiple endocrine neoplasia type 1 (MEN1), Carney complex (CNC), and MEN1-like syndrome (MEN4).

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to functionless pituitary adenoma and thyroid cancer, nonmedullary, 1. An important gene associated with Pituitary Adenoma is MIR15A (MicroRNA 15a), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ErbB signaling pathway. The drugs Prednisone and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid.

Disease Ontology : 12 A pituitary gland benign neoplasm that derives from glandular epithelial cells.

Wikipedia : 74 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 672)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 34.3 MEG3 HOTAIR
2 thyroid cancer, nonmedullary, 1 30.8 MEG3 MALAT1 HOTAIR H19
3 glioma 30.6 MIR15A MEG3 MALAT1 HOTAIR H19 CCAT2
4 malignant glioma 30.5 MEG3 MALAT1 HOTAIR H19
5 osteogenic sarcoma 30.4 MEG3 MALAT1 HOTAIR H19 CCAT2
6 endocrine gland cancer 30.1 MIRLET7A1 MIR26B MIR223 MIR15A
7 myeloma, multiple 29.9 MIRLET7E MIR15A MEG3 MALAT1 HOTAIR H19
8 kidney cancer 29.8 MIR15A MEG3 MALAT1 HOTAIR H19
9 renal cell carcinoma, nonpapillary 29.6 MIRLET7A1 MIR7-1 MIR212 MIR15A MALAT1 HOTAIR
10 ovarian disease 29.6 MIRLET7A1 MIR24-1 MIR223 MIR132
11 leukemia, chronic lymphocytic 29.5 MIRLET7A1 MIR24-1 MIR223 MIR16-1 MIR15A MIR132
12 gastrointestinal system disease 29.5 MIRLET7E MIRLET7A1 MIR24-1 MIR223 MIR15A
13 bladder cancer 29.4 MIR26B MIR223 MEG3 MALAT1 HOTAIR H19
14 melanoma 29.4 MIRLET7E MIR15A MIR128-1 MEG3 MALAT1 HOTAIR
15 nasopharyngeal carcinoma 29.3 MIR26B MIR24-1 MIR212 MIR15A MEG3 MALAT1
16 prostate disease 29.2 MIRLET7A1 MIR24-1 MIR223 MIR15A MEG3 MALAT1
17 reproductive system disease 29.2 MIRLET7A1 MIR7-1 MIR24-1 MIR223 MIR15A MIR132
18 lung cancer susceptibility 3 29.2 MIRLET7E MIRLET7A1 MIR212 MIR15A MEG3 MALAT1
19 parkinson disease, late-onset 29.1 MIR26B MIR24-1 MIR212 MIR132 MALAT1 HOTAIR
20 nervous system disease 29.0 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR15A
21 leukemia, acute myeloid 28.8 MIRLET7E MIR223 MIR212 MIR15A MIR128-1 MEG3
22 central nervous system disease 28.8 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR15A
23 gastric cancer 28.7 MIRLET7A1 MIR24-1 MIR223 MIR16-1 MEG3 MALAT1
24 prostate cancer 28.6 MIRLET7A1 MIR26B MIR223 MIR212 MIR16-1 MIR15A
25 pancreatic cancer 28.2 MIRLET7A1 MIR24-1 MIR223 MIR212 MIR16-1 MIR15A
26 ovarian cancer 28.1 MIRLET7E MIRLET7A1 MIR7-1 MIR26B MIR223 MEG3
27 hepatocellular carcinoma 26.8 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
28 pituitary adenoma 1, multiple types 12.9
29 pituitary adenoma, prolactin-secreting 12.9
30 familial isolated pituitary adenoma 12.9
31 acth-secreting pituitary adenoma 12.8
32 pituitary adenoma 5, multiple types 12.8
33 pituitary adenoma 4, acth-secreting 12.8
34 pituitary adenoma 2, growth hormone-secreting 12.7
35 pituitary adenoma 3, multiple types 12.7
36 functioning pituitary adenoma 12.6
37 growth hormone secreting pituitary adenoma 12.6
38 non-functioning pituitary adenoma 12.5
39 aip familial isolated pituitary adenomas 12.4
40 silent pituitary adenoma 12.4
41 mixed functioning pituitary adenoma 12.3
42 null pituitary adenoma 12.3
43 acromegaly 12.3
44 hypopituitarism 11.9
45 carney complex variant 11.8
46 tsh producing pituitary tumor 11.8
47 chromosome xq26.3 duplication syndrome 11.8
48 somatomammotropinoma 11.7
49 multiple endocrine neoplasia 11.7
50 adenoma 11.7

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
3
Pasireotide Approved Phase 4 396091-73-9 9941444
4
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
5
Metformin Approved Phase 4 657-24-9 14219 4091
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
leucovorin Approved Phase 4 58-05-9 6006 143
13
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
14
Cefazolin Approved Phase 4 25953-19-9 656510 33255
15
Cefdinir Approved Phase 4 91832-40-5 6915944
16
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
21
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
22
Cabergoline Approved Phase 4 81409-90-7 54746
23
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
24
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
25
lanreotide Approved Phase 4 108736-35-2
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27 Pharmaceutical Solutions Phase 4
28 Mitogens Phase 4
29 Adrenergic alpha-Agonists Phase 4
30 Adrenergic Agents Phase 4
31 Adrenergic Agonists Phase 4
32 Hypoglycemic Agents Phase 4
33
protease inhibitors Phase 4
34 HIV Protease Inhibitors Phase 4
35 Insulin, Globin Zinc Phase 4
36 insulin Phase 4
37 Dipeptidyl-Peptidase IV Inhibitors Phase 4
38 Sitagliptin Phosphate Phase 4
39 Incretins Phase 4
40 Analgesics, Non-Narcotic Phase 4
41 Analgesics Phase 4
42 Narcotics Phase 4
43 Analgesics, Opioid Phase 4
44 Cyclooxygenase Inhibitors Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Antirheumatic Agents Phase 4
47 Vitamin B Complex Phase 4
48 Folate Phase 4
49 Vitamin B9 Phase 4
50 Anti-Bacterial Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
3 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Unknown status NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
4 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
5 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
6 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
7 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
8 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
9 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
10 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
11 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
12 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
13 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
14 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
15 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
16 A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity Terminated NCT01861717 Phase 4 lanreotide
17 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
18 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
19 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
20 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
21 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
22 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
23 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
24 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
25 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
26 A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
27 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
28 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Recruiting NCT03621280 Phase 3 Levoketoconazole
29 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
30 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Active, not recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
31 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
32 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
33 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
34 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
35 A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas Unknown status NCT00993356 Phase 2 Preoperative lanreotide treatment
36 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
37 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
38 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
39 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
40 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
41 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
42 A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism Completed NCT01673646 Phase 2 Pasireotide LAR
43 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
44 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Completed NCT01915303 Phase 2 Pasireotide with or without cabergoline
45 Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients Completed NCT00171730 Phase 2 Pasireotide
46 Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies Completed NCT02274311 Phase 2 Clomiphene Citrate
47 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
48 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
49 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
50 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

40
Pituitary, Brain, Thyroid, Testes, Bone, Endothelial, Lung

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 7446)
# Title Authors PMID Year
1
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 61 46
17111382 2007
2
Multiple endocrine neoplasia type 1-associated cystic pancreatic endocrine neoplasia and multifocal cholesterol granulomas. 61 54
20403035 2010
3
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 61 54
20111911 2010
4
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 54 61
20106827 2010
5
Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. 61 54
19472104 2010
6
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 61 54
20150876 2010
7
Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. 54 61
19684062 2009
8
No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. 54 61
19919817 2009
9
Acromegaly pathogenesis and treatment. 54 61
19884662 2009
10
Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. 61 54
20045804 2009
11
Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. 61 54
19443539 2009
12
[Outcome of somatostatin analogue treatment in acromegaly]. 54 61
19617182 2009
13
The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. 54 61
19366855 2009
14
Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. 61 54
19356755 2009
15
GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. 54 61
19236640 2009
16
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. 61 54
19223528 2009
17
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. 54 61
19347192 2009
18
Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone. 61 54
18991502 2009
19
Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism. 61 54
19293545 2009
20
Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. 54 61
19153518 2009
21
Pituitary adenoma stem cells. 61 54
19582428 2009
22
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 61 54
18840925 2009
23
Update on the treatment of pituitary adenomas: familial and genetic considerations. 61 54
19170361 2008
24
Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. 61 54
19169048 2008
25
Large genomic deletions in AIP in pituitary adenoma predisposition. 54 61
18628514 2008
26
Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. 54 61
18410548 2008
27
Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary. 54 61
18633321 2008
28
Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. 61 54
18620995 2008
29
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. 61 54
18698020 2008
30
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. 61 54
18445999 2008
31
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. 54 61
18381572 2008
32
Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells. 61 54
18367633 2008
33
Multiple Endocrine Neoplasia type 1. 54 61
18249304 2008
34
Molecular and trophic mechanisms of tumorigenesis. 61 54
18226729 2008
35
Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. 61 54
18273074 2008
36
Misdiagnosis due to the hook effect in prolactin assay. 61 54
18685288 2008
37
Adrenomedullin expression in pituitary adenomas and nontumoral adenohypophyses. 54 61
17952853 2008
38
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. 54 61
19029774 2008
39
Effect of somatostatin on repair of ionizing radiation-induced DNA damage in pituitary adenoma cells GH3. 54 61
17552875 2008
40
Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma. 61 54
18079591 2007
41
Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features. 54 61
17993773 2007
42
The clinical, pathological, and genetic features of familial isolated pituitary adenomas. 61 54
17893250 2007
43
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. 61 54
17893251 2007
44
No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. 61 54
17914118 2007
45
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. 61 54
17524029 2007
46
Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. 54 61
17561883 2007
47
Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. 54 61
17420609 2007
48
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. 54 61
17244780 2007
49
The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. 61 54
17371465 2007
50
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. 61 54
17613551 2007

Variations for Pituitary Adenoma

Cosmic variations for Pituitary Adenoma:

9 (show top 50) (show all 59)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87132301 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 30
2 COSM87132318 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 30
3 COSM112988978 HRAS pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 30
4 COSM112988917 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 30
5 COSM93760866 GNAS pituitary,NS,adenoma,GH c.2530C>T p.R844C 20:58909365-58909365 30
6 COSM93761460 GNAS pituitary,NS,adenoma,GH c.2609A>T p.Q870L 20:58909541-58909541 30
7 COSM93761837 GNAS pituitary,NS,adenoma,GH c.2609A>G p.Q870R 20:58909541-58909541 30
8 COSM93760887 GNAS pituitary,NS,adenoma,GH c.2531G>A p.R844H 20:58909366-58909366 30
9 COSM93761140 GNAS pituitary,NS,adenoma,GH c.2530C>A p.R844S 20:58909365-58909365 30
10 COSM87642925 pituitary,NS,adenoma,GH c.94-402C>T p.? 20:58909365-58909365 30
11 COSM101967380 pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 30
12 COSM93086636 pituitary,NS,adenoma,GH c.604C>T p.R202C 20:58909365-58909365 30
13 COSM93726285 pituitary,NS,adenoma,GH c.559C>T p.R187C 20:58909365-58909365 30
14 COSM93726301 pituitary,NS,adenoma,GH c.560G>A p.R187H 20:58909366-58909366 30
15 COSM85346237 pituitary,NS,adenoma,GH c.635A>T p.Q212L 20:58909541-58909541 30
16 COSM85345830 pituitary,NS,adenoma,GH c.556C>T p.R186C 20:58909365-58909365 30
17 COSM93779606 pituitary,NS,adenoma,GH c.2488C>T p.R830C 20:58909365-58909365 30
18 COSM89474843 pituitary,NS,adenoma,GH c.*504C>T p.? 20:58909365-58909365 30
19 COSM93702294 pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 30
20 COSM93701960 pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 30
21 COSM93630265 pituitary,NS,adenoma,GH c.*507C>T p.? 20:58909365-58909365 30
22 COSM85345852 pituitary,NS,adenoma,GH c.557G>A p.R186H 20:58909366-58909366 30
23 COSM87642939 pituitary,NS,adenoma,GH c.94-401G>A p.? 20:58909366-58909366 30
24 COSM93726636 pituitary,NS,adenoma,GH c.638A>T p.Q213L 20:58909541-58909541 30
25 COSM93726530 pituitary,NS,adenoma,GH c.559C>A p.R187S 20:58909365-58909365 30
26 COSM93086945 pituitary,NS,adenoma,GH c.683A>T p.Q228L 20:58909541-58909541 30
27 COSM93779631 pituitary,NS,adenoma,GH c.2489G>A p.R830H 20:58909366-58909366 30
28 COSM93779988 pituitary,NS,adenoma,GH c.2567A>T p.Q856L 20:58909541-58909541 30
29 COSM93780281 pituitary,NS,adenoma,GH c.2567A>G p.Q856R 20:58909541-58909541 30
30 COSM101951743 pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 30
31 COSM93630681 pituitary,NS,adenoma,GH c.*586A>T p.? 20:58909541-58909541 30
32 COSM87643126 pituitary,NS,adenoma,GH c.94-402C>A p.? 20:58909365-58909365 30
33 COSM101951679 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
34 COSM93702186 pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 30
35 COSM93086649 pituitary,NS,adenoma,GH c.605G>A p.R202H 20:58909366-58909366 30
36 COSM101967337 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
37 COSM85346567 pituitary,NS,adenoma,GH c.635A>G p.Q212R 20:58909541-58909541 30
38 COSM93701978 pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 30
39 COSM89475152 pituitary,NS,adenoma,GH c.*504C>A p.? 20:58909365-58909365 30
40 COSM93726964 pituitary,NS,adenoma,GH c.638A>G p.Q213R 20:58909541-58909541 30
41 COSM89474878 pituitary,NS,adenoma,GH c.*505G>A p.? 20:58909366-58909366 30
42 COSM87643479 pituitary,NS,adenoma,GH c.94-226A>G p.? 20:58909541-58909541 30
43 COSM87643227 pituitary,NS,adenoma,GH c.94-226A>T p.? 20:58909541-58909541 30
44 COSM105721467 pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 30
45 COSM93086861 pituitary,NS,adenoma,GH c.604C>A p.R202S 20:58909365-58909365 30
46 COSM93631069 pituitary,NS,adenoma,GH c.*586A>G p.? 20:58909541-58909541 30
47 COSM93630284 pituitary,NS,adenoma,GH c.*508G>A p.? 20:58909366-58909366 30
48 COSM91331236 pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 30
49 COSM93087211 pituitary,NS,adenoma,GH c.683A>G p.Q228R 20:58909541-58909541 30
50 COSM93702535 pituitary,NS,adenoma,GH c.680A>G p.Q227R 20:58909541-58909541 30

Copy number variations for Pituitary Adenoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 ErbB signaling pathway hsa04012
3 Cell cycle hsa04110
4 Apoptosis hsa04210
5 Insulin signaling pathway hsa04910

Pathways related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 MIRLET7E MIRLET7A1 MIR7-1 MIR26B MIR223 MIR16-1
2 11.61 MIR138-2 MIR136 MIR132
3 11.28 MIR26B MIR212 MIR136 MIR132 MIR128-1
4 10.77 MIRLET7E MIRLET7A1
5 10.23 MEG3 HOTAIR

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 MIRLET7E MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223
2 extracellular vesicle GO:1903561 9.43 MIRLET7A1 MIR26B MIR24-1 MIR16-1 MIR15A MIR103A2

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.73 MIR223 MIR16-1 MIR15A MIR138-2
2 negative regulation of angiogenesis GO:0016525 9.71 MIR24-1 MIR212 MIR16-1 MIR15A
3 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.69 MIR16-1 MIR15A MIR138-2
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR16-1 MIR15A MIR138-2
5 negative regulation of blood vessel endothelial cell migration GO:0043537 9.63 MIR24-1 MIR212 MIR132
6 negative regulation of vascular endothelial cell proliferation GO:1905563 9.58 MIR24-1 MIR132
7 negative regulation of peptidyl-serine phosphorylation GO:0033137 9.57 MIR212 MIR132
8 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR223 MIR15A
9 miRNA mediated inhibition of translation GO:0035278 9.56 MIRLET7E MIRLET7A1 MIR212 MIR16-1 MIR15A MIR138-2
10 negative regulation of peptidyl-threonine phosphorylation GO:0010801 9.55 MIR15A MIR103A2
11 negative regulation of nitric oxide biosynthetic process GO:0045019 9.54 MIR212 MIR132
12 gene silencing by miRNA GO:0035195 9.53 MIRLET7E MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223
13 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.52 MIRLET7E MIRLET7A1
14 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.5 MIR24-1 MIR16-1 MIR15A
15 negative regulation of peptidyl-cysteine S-nitrosylation GO:1902083 9.48 MIR212 MIR132
16 positive regulation of endothelial cell apoptotic process GO:2000353 9.43 MIR24-1 MIR15A MIR132
17 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.37 MIR16-1 MIR15A
18 negative regulation of nitric-oxide synthase activity GO:0051001 9.33 MIR212 MIR138-2 MIR132

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIRLET7E MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....